Navigation Links
NeoPharm Provides Update on LE-SN38 Program

ical trials of the Company's drug product candidates, including, but not limited to, LE-SN38, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in financing, development, testing, regulatory approval, production, and marketing of the Company's drug and non-drug compounds including, but not limited to the Company's ability to develop a program for commercializing LE-SN38 and its other liposomal technology drug product candidates, the Company's funding of certain of its development projects in order to conserve its cash resources, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug and non-drug compounds, including, but not limited to, LE-SN38 and its other liposomal technology drug product candidates, that could slow or prevent products coming to market, uncertainty regarding the Company's ability to market its drug and non-drug products, including, but not limited to, LE-SN38 and its other liposomal technology drug product candidates, directly or through independent distributors, and other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission including its annual report on Form 10-K for the calendar year ended December 31, 2006. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on these forward-looking statements as a prediction of actual future results.

Contact

NEOPHARM, Inc.
Laurence Birch, President and Chief Executive Officer
lbirch@neopharm.com
847-406-1781


'"/>




Page: 1 2

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. XTL Provides Update on Phase I Clinical Trial of XTL-2125
3. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
4. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
5. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
6. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
7. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
8. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
9. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
10. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
11. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NeoPharm Provides Update Program
(Date:9/16/2014)... , Sept. 16, 2014   Vestagen Technical Textiles, ... patient experience at hospitals. The myComfort™ line of patient ... barrier fabric that is fluid repellant, breathable and in ... the growth of bacteria on the fabric i . ... plays in the chain of transmission. We want myComfort ...
(Date:9/16/2014)... Sept. 16, 2014  Synereca Pharmaceutics, Inc. ... orally active drugs that restore or increase ... a $1.4 million convertible debt financing. Accele ... sciences accelerator Accele Biopharma, Inc., led the ... nationally recognized private not-for-profit corporation focused on ...
(Date:9/16/2014)... N.Y. , Sept. 16, 2014 ... the world,s largest provider of health care products ... medical practitioners, announced today that Stanley M. Bergman, Henry ... will participate in a healthcare services panel at ...  Joining Mr. Bergman will be Dr. Stohler, Dean ...
Breaking Medicine Technology:New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4Henry Schein To Present At The Leerink Partners Services Roundtable 2
... pharmaceutical products - particularly those that are first-in-class, socially ... not only external disease state communication but also internal ... a product for a new or relatively unknown condition ... the new disease before introducing a new product to ...
... Company (NYSE: LLY ) today announced that the ... a prior ruling by the U.S. District Court for the ... the company,s method-of-use patent on Strattera® (atomoxetine). In the case ... et al, the court ruled in favor of Lilly, ...
Cached Medicine Technology:Building Support for a New Product Through Effective Internal Disease State Communication 2U.S. Court of Appeals Affirms Validity of Lilly's Strattera Patent 2
(Date:9/16/2014)... Dotinga HealthDay Reporter , MONDAY, ... baldness may face a higher risk of developing an aggressive ... new study suggests. But, the study authors noted that ... of baldness should be concerned. Their study only found an ... did not prove cause and effect. "It is conceivable ...
(Date:9/16/2014)... After working together for eight years and ... fertility centers in the late 1990s and early 2000s, Dr. ... hometown of New York City to launch Chelsea Fertility of ... , Chelsea Fertility NYC offers full service fertility treatment ... New York Tri-State Area, and provides equal access to care ...
(Date:9/16/2014)... New Jersey (PRWEB) September 16, 2014 ... Infinity Development Partners of San Antonio, TX. has been ... Army facilities located throughout the US, including Alaska and ... Army’s Energy Initiatives Task Force (EITF) and the Corps ... a $7 Billion MATOC primarily to fund renewable and ...
(Date:9/16/2014)... Alachua, FL (PRWEB) September 16, 2014 ... technology company focused on the peripheral nerve repair market, ... the American Society for Surgery of the Hand (ASSH) ... John B. Hynes Convention Center in Boston, MA. , ... outcomes in surgical nerve repair, featuring a discussion by ...
(Date:9/16/2014)... September 16, 2014 Much of the ... major extended drought crisis that in many regions affects ... the many individuals who are dedicated to solving the ... solutions overlook large portion of the problem. Partial solutions, ... crises.     , Grigg explained his, “total water management” concept ...
Breaking Medicine News(10 mins):Health News:Male Pattern Baldness Tied to Prostate Cancer, Study Suggests 2Health News:Male Pattern Baldness Tied to Prostate Cancer, Study Suggests 3Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 2Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 3Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 4Health News:Solar Construction Opportunity at U.S Army Installations Awarded to Pfister Energy & Infinity Development 2Health News:AxoGen, Inc. to Host Surgeon Education Event at American Society for Surgery of the Hand 2014 Annual Meeting 2Health News:AxoGen, Inc. to Host Surgeon Education Event at American Society for Surgery of the Hand 2014 Annual Meeting 3Health News:Drought Solutions Overlook Too Many Factors Water Policy Expert Warns Sharon Kleyne 2Health News:Drought Solutions Overlook Too Many Factors Water Policy Expert Warns Sharon Kleyne 3
... men after bypass surgery, according to a new study done ... say whether the //results are due to medical or psychosocial ... outcomes after bypass surgery than men. Most have attributed this ... generally older, sicker, and have fewer social supports. In this ...
... is when symptoms have lasted for less than three ... self-management program that includes group classes, exercise sheet handouts, ... manage their back pain. ,Researchers from Indiana University ... low back pain. The program focuses on boosting confidence ...
... study shows hydrotherapy, or water exercise, may improve strength and ... studied more than 100 patients with osteoarthritis who were older ... first group exercised three times a week in a swimming ... did not exercise at all. Both the water and gym ...
... may improve strength and mobility in patients with osteoarthritis.// ... who were older than age 50. Patients were divided into ... in a swimming pool, the second exercised in a gym, ... water and gym programs focused on resistance exercises. ,Results ...
... lasted for less than three months. ,A new study ... sheet// handouts, and telephone follow-up calls may help patients ... from Indiana University developed a self-management program for poor, ... on boosting confidence in order to increase their motivation ...
... reducing the signs of aging in the neck. The procedure involves ... reduce the saggy appearance of the neck. Researchers say this new ... are often changes in the neck and face including the loss ... of fat in the neck. This causes the skin to sag. ...
Cached Medicine News:
... For the quantitative determination ... human serum. Progesterone ... the principle of competitive ... the test specimen and ...
... AutoDELFIA Insulin kit is for the ... and heparin plasma using the AutoDELFIA ... used in the investigation, diagnosis and ... blood glucose level). The analytical sensitivity ...
ELISA for the detection of Insulin....
ELISA for the detection of 17a OH Progesterone....
Medicine Products: